Skip to content
GenBio, Inc. Discusses Entering the 191 Billion Dollar Anti-Inflammatory Market, Potential of Their Research, Crowdfunding Offering, and Their Strategic Partnership with Dakshidin Corp. (OTC:Pink DKSC) on The Stock Day Podcast episode artwork

EPISODE · May 17, 2021 · 9 MIN

GenBio, Inc. Discusses Entering the 191 Billion Dollar Anti-Inflammatory Market, Potential of Their Research, Crowdfunding Offering, and Their Strategic Partnership with Dakshidin Corp. (OTC:Pink DKSC) on The Stock Day Podcast

from Stock Day Media · host Stock Day Media

The Stock Day Podcast welcomed GenBio, Inc. and Dakshidin Corp (OTC Pink: DKSC)("the Company"). Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company with unrivaled (and possibly unique) research expertise based on an unexpected yet vitally important medical research breakthrough - described by the US scientific team as “never seen before”, and Dakshidin Corp. CEO, Chris Haigh, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Episode metadata supplied by the publisher feed · Published May 17, 2021

Embed this episode

Ready to play

GenBio, Inc. Discusses Entering the 191 Billion Dollar Anti-Inflammatory Market, Potential of Their Research, Crowdfunding Offering, and Their Strategic Partnership with Dakshidin Corp. (OTC:Pink DKSC) on The Stock Day Podcast

0:00 9:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Stock Day Media?

This episode is 9 minutes long.

When was this Stock Day Media episode published?

This episode was published on May 17, 2021.

Can I download this Stock Day Media episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!